Loading
A phase 2 trial of Gemcitabine, Nogapendekin alfa inbakicept in ovarian cancer, run by ImmunityBio, Inc., now recruiting.
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer is a phase 2 interventional study registered as NCT06710288 by ImmunityBio, Inc., with 20 participants planned, started 2024-11-06 and due to reach its primary completion in 2027-05. Interventions recorded: Gemcitabine, N-803, M-CENK. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Cytokines & engineered cytokines, Cytotoxic chemotherapy.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Cytokines & engineered cytokines.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Cytokines & engineered cytokines.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Gemcitabine.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/